European Journal of Clinical Pharmacology

, Volume 7, Issue 5, pp 369–373 | Cite as

Binding of rifampicin by human plasma proteins

  • G. Boman
  • V. A. Ringberger


The binding of rifampicin to human plasma proteins has been investigated by equilibrium dialysis. Plasma from eleven healthy subjects not taking drugs bound 87–91% of added rifampicin. Binding was lower (84–88%) in plasma from ten tuberculous patients on long-term treatment with rifampicin. Physiological concentrations of human albumin, gamma globulin and fibrinogen bound 41, 10 and 8%, respectively, of added rifampicin. Isoniazid, p-aminosalicylic acid, streptomycin and ethambutol did not significantly affect rifampicin binding to plasma proteins.

Key words

Rifampicin plasma protein binding isoniazid p-aminosalicylic acid streptomycin ethambutol 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aoyagi, T.: Protein binding of rifampicin to different individual sera. Scand. J. resp. Dis. (Suppl. 84), 44–49 (1973)Google Scholar
  2. Beeuwkes, H., Buytendijk, H. J., Maesen, F. P. V.: Der Wert des Rifampicin bei der Behandlung von Patienten mit bronchopulmonären Affektionen. Arzneimittel-Forsch.19, 1283–1285 (1969)Google Scholar
  3. Binda, G., Domenichini, E., Gottardi, A., Orlandi, B., Ortelli, E., Pacini, B., Fowst, G.: Rifampicin, a general review. Arzneimittel-Forsch.21, 1907–1978 (1971)Google Scholar
  4. Boman, G., Hanngren, Å., Malmborg, A.-S., Borgå, O., Sjöqvist, F.: Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S. Lancet1971 I, 800Google Scholar
  5. Boman, G.: Protein binding of rifampicin. A review. Scand. J. resp. Dis. Suppl.84, 40–43 (1973)Google Scholar
  6. Boman, G.: Serum concentration and half-live of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Europ. J. clin. Pharmacol.7, 217–225 (1974)Google Scholar
  7. Boman, G., Malmborg, A.-S.: Rifampicin in plasma and pleural fluid after single oral doses. Europ. J. clin. Pharmacol.7, 51–58 (1974)Google Scholar
  8. Borgå, O., Azarnoff, D. L., Sjöqvist, F.: Species differences in the plasma protein binding of desipramine. J. Pharm. Pharmacol.20, 571–572 (1968)Google Scholar
  9. Chignell, C. F., Starkweather, D. K.: Species differences in the binding of phenylbutazone to plasma albumin. Pharmacology5, 235–244 (1971)Google Scholar
  10. Curci, G., Ninni, A., D'Alessio, A., Iodice, F.: Interferenze fisico-chimiche a livello del legame proteico fra PAS ed altri chemioterapici. XIX Congresso Italiano di Tisiologia3, 955–957 (1968)Google Scholar
  11. Dost, F. H.: Grundlagen der Pharmakokinetik, pp. 106–108. Stuttgart: Thieme 1968Google Scholar
  12. Doumas, B. T., Watson, W. A., Biggs, H. G.: Albumin standards and the measurement of serum albumin with bromcresol green. Clin. chim. Acta31, 87–96 (1971)Google Scholar
  13. Dukor, P., Schumann, G., Dietrich, F. M.: Immunological studies with rifampicin. Scand. J. resp. Dis. (Suppl. 84), 73–82 (1973)Google Scholar
  14. Ehrnebo, M., Agurell, S., Jalling, B., Boréus, L. O.: Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Europ. J. clin. Pharmacol.3, 189–193 (1971)Google Scholar
  15. Guiliano, V., Ninni, A.: Indagini sul legame delle rifamicine SV ed AMP con le proteine del siero. XVIII Congresso Italiano di Tisiologia2, 154–155 (1966)Google Scholar
  16. Gundert-Remy, U., Klett, M., Weber, E.: Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum. Europ. J. clin. Pharmacol.6, 133–136 (1973)Google Scholar
  17. Lunde, P. K. M., Rane, A., Yaffe, S. J., Lund, L., Sjöqvist, F.: Plasma protein binding of diphenylhydantoin in man. Clin. Pharmacol. Ther.11, 846–855 (1970)Google Scholar
  18. Mashimo, K.: Rifampicin: pharmacological and clinical studies. Prog. Antimicrob. Anticancer Chemother.2, 1198–1205. Baltimore: University Park Press 1970Google Scholar
  19. Nilsson, B. S., Boman, G., Bullock, W. W.: Detection of rifampicin binding immunoglobulins. Scand. J. resp. Dis. (Suppl. 84), 50–52 (1973)Google Scholar
  20. Riess, W.: The optimum dosage schedule for Rimactane. A symposium on Rimactane, pp. 36–42. Basel: CIBA 1968Google Scholar
  21. Riess, W., Schmid, K., Keberle, H., Dettli, L., Spring, P.: Pharmacokinetic studies in the field of rifamycins. Prog. Antimicrob. Anticancer Chemother.2, 905–913. Baltimore: University Park Press 1970Google Scholar
  22. Sato, S., Motomiya, M., Amizuka, T., Fumakoshi, H.: Binding of streptomycin, paraaminosalicylic acid and isonicotinic acid to serum protein. Sci. Rep. Res. Inst. Tohoku Univ.8, 111–135 (1958)Google Scholar
  23. Seydel, J. K.: Physico-chemical studies on rifampicin. Antibiot. et Chemother. (Basel)16, 380–391 (1970)Google Scholar
  24. Stockholm Workshop on Rifampicin, 1972. Scand. J. resp. Dis. Suppl. 84 (1973)Google Scholar

Copyright information

© Springer-Verlag 1974

Authors and Affiliations

  • G. Boman
    • 1
    • 2
  • V. A. Ringberger
    • 1
    • 2
  1. 1.Department of Clinical PharmacologyHuddinge HospitalStockholmSweden
  2. 2.Department of Thoracic MedicineKarolinska HospitalStockholmSweden

Personalised recommendations